Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating AFib-RVR.

The post Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation appeared first on Clinical Trials Arena.